Myriad's Alzheimer's drug misses targets in trial (Reuters)


Reuters - Myriad Genetics Inc. on Monday said
its drug Flurizan failed to effect a significant improvement in
patients with mild to moderate Alzheimer's disease, though some
benefit was seen in certain patients with mild forms of the
disease.

Read more...